We are stuck waiting for guidance in regards to production and sales. We know that Hikma is ramping. Piper made a good point that some of the expansion might be to show potential customers that UNS has the ability to ramp:
"We think a major driver of the expansion is entering a growing commercial phase with the Sanofi
and Hikma partnerships. Perhaps the desire to show current development stage partners,
recent "option signers", and/or prospective new business development collaborators, Unilife’s
ability to "scale" is also contributing to the initiative."
UNS Price at posting:
44.0¢ Sentiment: Buy Disclosure: Held